Research articlePublished 9 Apr 2025
Small Molecule Inhibitors of PFKFB3 as Therapeutic Targets for Atherosclerosis in ApoE-/-mice
1Crucial Cardiovascular Laboratory, First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, China; 2Department of Cardiovascular Medicine, The First Hospital of Lanzhou University, Lanzhou City, Gansu Province, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Atherosclerotic cardiovascular disease, a leading cause of global mortality and morbidity, is driven by chronic inflammation and metabolic dysregulation. The inhibition of monocyte-macrophage inflammatory responses is a critical therapeutic strategy, as these cells play a central role in atherosclerosis progression. Glycolysis, a universal metabolic pathway, is regulated by the bifunctional enzyme PFKFB3, which modulates intracellular levels of fructose‑ 2,6‑bisphosphate (Fru‑2,6‑BP). Despite the potential of PFKFB3 inhibitors like 3PO in atherosclerosis treatment, their mechanisms and therapeutic efficacy remain incompletely understood. This study investigates the role of PFKFB3 inhibition in atherosclerosis using ApoE^‑/‑^ mice, highlighting its impact on monocyte‑macrophage responses and plaque formation. Our findings suggest that 3PO-mediated PFKFB3 inhibition attenuates atherosclerosis by reducing inflammatory markers and vascular remodeling, offering a promising therapeutic avenue.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDiagnostic Pathology: Open Access
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Lan Yu”
- BylineArticles whose byline prints “Wang Runqing”
- BylineArticles whose byline prints “Zhang Jin”